AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03945357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Comparison of saline solution rinse vs antibiotic rinse
Study NCT01543828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: delivered via single-dose dry-powder inhaler
Study NCT01543828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: delivered via single-dose dry-powder inhaler
Study NCT03429881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stripping versus laser CO2
Description: Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.
Study NCT02630342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mock MRI scanner
Description: Using a mock scanner for preparation for MRI
Study NCT02630342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preparation materials
Description: links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.
Study NCT02630342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life Specialist preparation
Description: Child Life Therapist will coordinate the prepartion of the child
Study NCT02630342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Review Preparation Materials
Description: Review of preparation materials at the hospital with member of research team
Study NCT02451579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine Cetirizine Hydrochloride
Description: Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
Study NCT02451579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
Study NCT02937194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal oral health instruction + pamphlets distribution
Description: Personal oral health instruction (OHI) and oral health pamphlets distribution
Study NCT02937194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlets distribution
Description: Oral health pamphlets distribution
Study NCT01992133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study NCT01992133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03126526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food specific Inhibitory control training
Description: It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include photos of food and non-food.
Study NCT03126526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Description: It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future.
Study NCT03126526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation intentions
Description: It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future.
Study NCT03126526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General inhibitory control training
Description: It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include only non-food pictures.
Study NCT00711425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™
Description: OsseoSpeed™, all dimensions
Study NCT03686098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary soy
Description: Soy isoflavones delivered through diet, assisted by a detailed food guide for locally available soy-based foods.
Study NCT03686098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Supplement
Description: Soy isoflavones delivered in extracted form
Study NCT03579420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief lifestyle program
Description: 3-session program for modification of lifestyle habits (exercise and diet)
Study NCT03579420 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lifestyle program
Description: 6-session program for modification of lifestyle habits (exercise and diet)
Study NCT02445118 — intervention group
Intervention type: OTHER
Intervention: Adipose Allograft Matrix (AAM) injection
Description: Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
Study NCT01943513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB023
Description: Intravenous (IV) infusions
Study NCT01943513 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT00630851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil (Aricept)
Description: Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
Study NCT00630851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets orally once daily for 6 months
Study NCT00396994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low magnitude mechanical stimulation
Description: 10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
Study NCT00396994 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham low magnitude mechanical stimulation
Description: 10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
Study NCT03251495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxchora
Description: Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
Study NCT03141827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin 40 IU, nasal spray, single dose
Study NCT03141827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, nasal spray, single dose
Study NCT01079273 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: egg-derived A/H1N1 pandemic influenza vaccine
Description: One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
Study NCT02903251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin spray
Description: 6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.
Study NCT02903251 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intranasal spray without oxytocin
Description: 6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
Study NCT02847806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Estradiol (Insulin sensitivity)
Study NCT02847806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Testosterone (Insulin sensitivity)
Study NCT04121390 — intervention group
Intervention type: BEHAVIORAL
Intervention: Newborn Parenting Class
Description: Newborn Parenting Class designed by Mount Sinai Parenting Center. The class is 1-hour long and taught be pediatric attending and residents to all families who deliver well babies at Mount Sinai.
Study NCT02320942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
Study NCT02786238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Description: See description of treatment arm.
Study NCT02786238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Treatment (ABT)
Description: See description of treatment arm. \*\*Cherokee Nation members receive only the ABT intervention as they are in an open, feasibility trial and are not randomized.\*\*
Study NCT01211548 — intervention group
Intervention type: OTHER
Intervention: contrast CTA of the CAP
Description: CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
Study NCT00946257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
Study NCT02128048 — intervention group
Intervention type: DEVICE
Intervention: Assessment of body composition and muscle function
Description: Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
Study NCT01204580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE + METFORMIN
Description: Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
Study NCT03159156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Tension
Description: Described above.
Study NCT03159156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiration Control
Description: Described above.
Study NCT03159156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Tension/Respiration Control
Description: Described above.
Study NCT01038570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon®/- Spray
Description: 3 sprays corresponding to 24 IU in each nostril
Study NCT01038570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum (Sodium chloride)
Description: Sodium chloride 0.9 % (0.3 ml) in each nostril
Study NCT01984242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
Description: Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
Study NCT01984242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
Description: Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
Study NCT01984242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
Study NCT01984242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
Study NCT01984242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
Study NCT00948675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
Study NCT00948675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 \[maximum possible dose of 900 milligrams (mg)\] intravenously infused over 30 minutes.
Study NCT00948675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 \[maximum possible dose of 900 milligrams (mg)\] intravenously infused over 30 minutes.
Study NCT00948675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
Study NCT00948675 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
Study NCT00159965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: flexible dose sertraline
Study NCT00159965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: flexible dose placebo
Study NCT04056143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pharmacogenomics
Description: Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.
Study NCT03932266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
Study NCT03932266 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
Study NCT03932266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
Study NCT03932266 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
Study NCT03932266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
Study NCT03932266 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
Study NCT03932266 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
Study NCT03872999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional brain imaging without any contrast agent
Description: During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min).
Study NCT04072588 — intervention group
Intervention type: PROCEDURE
Intervention: vaginal cuff prolapse surgery
Description: Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
Study NCT03891719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral cleft lip rhinoplasty
Description: * Perform marking with methylene blue tattoo marks~* Inject Local anesthetic solution with epinephrine~* Harvest auricular cartilage~* Make the incisions parallel the lip scar, extende into the marginal incision and encompass any alar webbing. The incisions outline the entirety of the lower lateral cartilage and create sliding chondrocutaneous flap. This flap combines with reverse U incision.~* Harvest septal bony cartilaginous unit for grafting the caudal septum and suspend the medial crural cartilages~* Create dome symmetry at the cartilage level and reconstruct nasal tip with other grafts (shield-type tip graft, cap graft, alar batten graft)~* Dorsal augmentation~* Lip reconstruction and alar base repositioning.~* Closure and repair vestibular deficiency with the reverse-U component of the chondrocutaneous flap at the alar rim.
Study NCT02206659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02206659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00383890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine HCL Injection
Study NCT00383890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03734185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning and Coping
Description: 'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
Study NCT03734185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Learning and Coping
Description: 'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
Study NCT04514393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intravenous methotrexate at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 of all cycles，for up to 4 cycles.
Study NCT04514393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral ibrutinib will be given at a dose of 560 mg daily and will be continued daily after completion of methotrexate and temozolomide.Ibrutinib is continued until disease progression, intolerable toxicity or death.
Study NCT04514393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral temozolomide will be given at 150mg/m2 from day1 to day 5 every 4 of all cycles，for up to 4 cycles.
Study NCT00116922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID
Description: \[Rosiglitazone 2mg/ Metformin 500mg\] twice daily
Study NCT01072942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro InhaIe, BAYQ3939)
Description: Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
Study NCT01072942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TID for 10 days
Study NCT01968265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISIS-GCCRRx
Description: 3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
Study NCT01968265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
Study NCT01654107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persistence Targeted Smoking Cessation
Description: 8-weeks of smoking cessation counseling (Persistence Targeted Smoking Cessation)
Study NCT01654107 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clearing The Air
Description: 8-weeks counseling + 12-weeks nicotine lozenge based on NCI protocol, Clearing The Air
Study NCT01654107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenge
Description: 12-weeks 4mg nicotine lozenge
Study NCT01654107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: 12-weeks 4mg nicotine lozenge
Study NCT02697409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Against Tobacco intervention
Study NCT00439075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP
Study NCT00439075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Study NCT03561948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.